17,337 Shares in ADMA Biologics, Inc. (NASDAQ:ADMA) Bought by Centiva Capital LP

Centiva Capital LP purchased a new stake in shares of ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 17,337 shares of the biotechnology company's stock, valued at approximately $297,000.

Several other hedge funds have also added to or reduced their stakes in ADMA. Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its position in shares of ADMA Biologics by 1.3% in the 4th quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 50,466 shares of the biotechnology company's stock worth $865,000 after purchasing an additional 645 shares during the last quarter. Oregon Public Employees Retirement Fund lifted its stake in ADMA Biologics by 1.3% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 55,600 shares of the biotechnology company's stock valued at $954,000 after buying an additional 700 shares during the period. Summit Investment Advisors Inc. boosted its holdings in ADMA Biologics by 3.3% during the fourth quarter. Summit Investment Advisors Inc. now owns 23,560 shares of the biotechnology company's stock worth $404,000 after buying an additional 746 shares during the last quarter. Mutual of America Capital Management LLC boosted its holdings in ADMA Biologics by 2.1% during the fourth quarter. Mutual of America Capital Management LLC now owns 35,807 shares of the biotechnology company's stock worth $614,000 after buying an additional 751 shares during the last quarter. Finally, Maryland State Retirement & Pension System grew its position in shares of ADMA Biologics by 1.1% during the 4th quarter. Maryland State Retirement & Pension System now owns 79,607 shares of the biotechnology company's stock worth $1,365,000 after buying an additional 897 shares during the period. Institutional investors own 75.68% of the company's stock.

Analyst Ratings Changes

Several research analysts recently weighed in on the stock. Cantor Fitzgerald reissued an "overweight" rating and set a $25.00 price objective on shares of ADMA Biologics in a research note on Tuesday, March 4th. Raymond James boosted their price target on shares of ADMA Biologics from $25.00 to $32.00 and gave the company a "strong-buy" rating in a report on Thursday, May 8th. Finally, StockNews.com downgraded ADMA Biologics from a "hold" rating to a "sell" rating in a research note on Friday, May 9th. One investment analyst has rated the stock with a sell rating, three have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $24.25.

ADMA Biologics Stock Up 2.6%

NASDAQ:ADMA traded up $0.49 during trading hours on Friday, reaching $19.69. 2,523,120 shares of the stock were exchanged, compared to its average volume of 3,711,929. The stock has a market cap of $4.68 billion, a PE ratio of 70.32 and a beta of 0.57. ADMA Biologics, Inc. has a twelve month low of $8.91 and a twelve month high of $25.67. The firm has a 50 day moving average of $20.44 and a 200 day moving average of $18.82. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last announced its earnings results on Wednesday, May 7th. The biotechnology company reported $0.14 EPS for the quarter, missing the consensus estimate of $0.16 by ($0.02). The business had revenue of $114.80 million for the quarter, compared to analyst estimates of $116.40 million. ADMA Biologics had a return on equity of 53.20% and a net margin of 17.80%. The business's revenue for the quarter was up 40.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.08 EPS. On average, equities analysts expect that ADMA Biologics, Inc. will post 0.51 earnings per share for the current year.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.